Skip to main content
. 2022 Jul 2;13(8):1531–1546. doi: 10.1007/s13300-022-01285-1

Table 1.

Baseline characteristics of patients included in the study (n = 196)

Characteristics Total n = 196 No complications (n = 94) Microangiopathy only (n = 51) Macroangiopathy only (n = 9) Microangiopathy and macroangiopathy (n = 42) P**
Age (years), mean (SD) 44.5 (16) 39.1 (14.4) 44.68 (15.3) 41.6 (14.3) 55.7 (12.5)  < 0.0001
Duration of diabetes (years), mean (SD) 26.1 (12.2) 21.4 (9.3) 27.74 (12.8) 22.4 (9.8) 34.7 (12.4)  < 0.0001
Female, n (%) 105 (53.6) 53 (56.4) 28 (54.9) 4 (44.4) 19 (45.2) 0.31
Treatment (pump*), n (%) 113 (57.65) 52 (55.3) 31 (60.8) 5 (55.5) 25 (59.5) 0.78
HbA1c (%/mmol/ml), mean (SD) 8.1 (1.4) /65.5 (11.1) 8.1(1.2) /64.8(9.3) 8.4 (1.9) /68.4 (15.3) 8.0 (1.1) /63.9 (8.6) 8 (1.2) /63.6 (9.5) 0.61
BMI (kg/m2), mean ± SD 25.78 (4.5) 25.3 (3.7) 24.2 (2.2) 26.2 (5.3) 26.5 (5.1) 0.17
Hypertension, n (%) 71 (36.6) 16 (17) 20 (39.2) 7 (77.8) 34 (81)  < 0.0001
SBP, mean ± SD 125(13.9) 122(12) 126 (15) 123(12.7) 130 (14.7) 0.001
DBP, mean ± SD 74(9.6) 71(8.0) 74(11.6) 73(8.5) 76(9.8) 0.27
Dyslipidemia, n (%) 78 (39.6) 20 (21.3) 26 (51) 6 (66.7) 29 (69)  < 0.0001
Total cholesterol (mmol/l), mean (SD) 4.9 (0.9) 4.93 (1) 4.89 (0.9) 5 (1.1) 4.7 (0.9) 0.14
LDL cholesterol (mmol/l), mean (SD) 2.63 (0.8) 2.70 (0.9) 2.65 (0.7) 2.8 (0.8) 2.4 (0.6) 0.05
Triglycerides (mmol/l), mean (SD) 1.75 (0.5) 1.74 (0.5) 1.83 (0.6) 1.7 (0.5) 1.7 (0.5) 0.74
HDL cholesterol (mmol/l), mean (SD) 1.00 (0.5) 0.97 (0.5) 0.99 (0.5) 0.9 (0.3) 1.1 (0.5) 0.09
GFR (< 60 ml/min/1.73 m2), n (%) 12 (6.1) 1 (1.1) 3 (5.9) 0 (0.0) 8 (19) 0.001
Current smokers, n (%) 45 (22.9) 20 (21.3) 13 (25.5) 3 (33.3) 11 (26.2) 0.68
Current and former smokers, n (%) 51 (26.3) 21 (22.3) 15 (29.4) 4 (44.4) 13 (31) 0.39

HbA1c glycated hemoglobin, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL low-density lipoprotein, HDL high-density lipoprotein, GFR glomerular filtration rate by CKD-EPI

aTreatment by insulin pump versus multiple injection

bComparison between patients without complication (column 3) and those with both micro and macroangiopathy (column 6)